Drugs / pexmetinib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01496495 | Jan 2012 → Dec 2014 | myelodysplastic syndrome | Array BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT00916227 | Jun 2009 → Jan 2012 | myelodysplastic syndrome | Array BioPharma | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04074967 | Jun 2020 → Dec 2024 overdue | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, renal cell carcinoma | Dan Zandberg | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pexmetinib | “Array BioPharma provided the p38 inhibitor pexmetinib (ARRY614) and participated in its phase I study (ClinicalTrials.gov: NCT01496495).” PMID 34320342 ↗ Jul 2021 |
| Known as | ARRY614 | “Array BioPharma provided the p38 inhibitor pexmetinib (ARRY614) and participated in its phase I study (ClinicalTrials.gov: NCT01496495).” PMID 34320342 ↗ Jul 2021 |
| Action | Inhibit | “Tyrosine-protein kinase TIE-2 inhibitor” CHEMBL3991932 ↗ |
| Modality | Small molecule | — CHEMBL3991932 ↗ |
| Route | Oral | “ARRY-614, p38/Tie2 inhibitor; oral” NCT00916227 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL3991932 ↗ |
| Target | TEK | “Tyrosine-protein kinase TIE-2 inhibitor” CHEMBL3991932 ↗ |